Sera Prognostics (SERA) Set to Announce Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) is scheduled to release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Sera Prognostics to post earnings of ($0.22) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.08 million. During the same quarter last year, the firm posted ($0.34) earnings per share. On average, analysts expect Sera Prognostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sera Prognostics Stock Performance

Shares of SERA stock traded up $0.28 during mid-day trading on Tuesday, hitting $8.23. 4,951 shares of the stock were exchanged, compared to its average volume of 176,017. The stock’s fifty day simple moving average is $7.36 and its two-hundred day simple moving average is $7.76. Sera Prognostics has a 12-month low of $1.65 and a 12-month high of $12.35.

Insider Buying and Selling

In related news, CFO Austin Aerts sold 5,056 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $7.57, for a total transaction of $38,273.92. Following the transaction, the chief financial officer now owns 298,665 shares of the company’s stock, valued at $2,260,894.05. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, CEO Zhenya Lindgardt sold 12,327 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total value of $91,466.34. Following the completion of the sale, the chief executive officer now owns 856,918 shares in the company, valued at $6,358,331.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Austin Aerts sold 5,056 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $7.57, for a total transaction of $38,273.92. Following the completion of the sale, the chief financial officer now owns 298,665 shares of the company’s stock, valued at approximately $2,260,894.05. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,543 shares of company stock valued at $409,179 over the last quarter. 15.80% of the stock is currently owned by insiders.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.